Cardiovascular Diabetology

AUGUST 6, 2024

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.

Coronary Artery Disease 98

Coronary Artery Disease Diabetes Myocardial Infarction Heart Failure 98

Hypertension Journal

OCTOBER 11, 2023

BACKGROUND:Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined.METHODS:This retrospective observational cohort study evaluated 50 316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. were women.

Hypertension 40

Hypertension Kidney Disease Heart Failure Risk Factors 40

Stroke Journal

FEBRUARY 1, 2024

Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.

Diabetes 40

Diabetes Stroke Strokes Kidney Disease 40

DAIC

SEPTEMBER 11, 2024

A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. million U.S.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

Stroke Journal

FEBRUARY 1, 2024

million (2019) and projected to reach 4.90 million by 2030 according to the Global Burden of Disease Study. Autoimmune diseases are increasingly associated with chronic conditions and may modify risks by altering underlying pathophysiology. to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27

Inpatient 40

Inpatient Stroke Strokes Coronary Artery Disease 40

Cardiometabolic Health Congress

JULY 25, 2023

Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiometabolic Health Congress

JULY 10, 2024

Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression. A Pioneering Journey: The Life and Legacy of Dr. George L. Bakris Dr. George L. When I heard of his passing, I felt quite sad.

Hypertension 52

Hypertension Education Blood Pressure Kidney Disease 52